NewcelX Ltd. (NCEL)
NASDAQ: NCEL · Real-Time Price · USD
3.190
-0.060 (-1.85%)
Sep 9, 2026, 10:26 AM EDT - Market open
NewcelX Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
12
Market Cap
18.43M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cerenome | 4.20M |
| Dyadic International | 3.80M |
| Lipocine | 1.57M |
| Allarity Therapeutics | 345.00K |
| Neuphoria Therapeutics | -13.27K |
NCEL News
- 19 days ago - NewcelX registers to sell 694K common shares for holders - TheFly
- 5 weeks ago - NewcelX announces pricing of $1.4M equity financing - TheFly
- 5 weeks ago - NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing - GlobeNewsWire
- 1 month ago - NewcelX announces Brazil patent for cell selection, enrichment technology - TheFly
- 1 month ago - NewcelX initiated with a Buy at Laidlaw - TheFly
- 2 months ago - NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board - GlobeNewsWire
- 2 months ago - NewcelX completes Type B Pre-IND meeting with FDA for NCEL-101 - TheFly
- 2 months ago - NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes - GlobeNewsWire